PDS Biotechnology
PDSB
78 hedge funds and large institutions have $39.7M invested in PDS Biotechnology in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 25 reducing their positions, and 12 closing their positions.
3% more call options, than puts
Call options by funds: $1.62M | Put options by funds: $1.58M
0.27% less ownership
Funds ownership: 25.74% → 25.47% (-0.27%)
0% less capital invested
Capital invested by funds: $39.9M → $39.7M (-$199K)
4% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 25
3% less funds holding
Funds holding: 80 → 78 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.64M |
| 2 |
BlackRock
New York
|
+$387K |
| 3 |
State Street
Boston,
Massachusetts
|
+$263K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$247K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$142K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$876K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$643K |
| 3 |
Two Sigma Investments
New York
|
-$584K |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
-$412K |
| 5 |
LPL Financial
San Diego,
California
|
-$387K |
PDSB Hedge Fund Activity: Q3 2023 in Review
78 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q3 2023, worth a combined $39.7M — down 0.5% from $39.9M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PDSB and 10 opened new positions — a net loss of 2 holders — while 25 trimmed existing stakes and 24 added.
The largest buyer was Tang Capital Management, adding an estimated $1.64M. The largest seller was Two Sigma Advisers, cutting an estimated $876K.
- 78 institutional investors held PDS Biotechnology (PDSB) as of Q3 2023, down from 80 in Q2 2023.
- Funds reported $39.7M of PDS Biotechnology stock for Q3 2023, down 0.5% quarter-over-quarter.
- 10 funds opened new PDS Biotechnology positions in Q3 2023 and 12 closed out, a net change of -2 holders.
- The largest PDS Biotechnology buyer in Q3 2023 was Tang Capital Management, an estimated $1.64M added.
- The largest PDS Biotechnology seller in Q3 2023 was Two Sigma Advisers, an estimated $876K sold.
Based on aggregated 13F filings for Q3 2023.